title: [Modern drug therapy in cardiovascular intensive care medicine].
abstract: Vasoactive drugs and inotropes are important in the hemodynamic management of patients with cardiogenic shock despite modest volume administration. Currently, the concept of cardiac relief is pursued in the treatment of acute heart failure. In this article we present the use of different drugs in the intensive care unit for acute heart failure and cardiogenic shock. In acute heart failure catecholamines are only used during the transition from heart failure to cardiogenic shock. Here, the therapeutic concept of ventricular unloading is more sought after. This can be achieved by the use of diuretics, nitrates, levosimendan (inodilatator), or in the future serelaxin. The hemodynamic management in cardiogenic shock occurs after moderate volume administration with dobutamine to increase inotropy. If no adequate perfusion pressures are achieved, norepinephrine can be administered as a vasopressor. If there is still no sufficient increase in cardiac output, the inodilatator levosimendan can be used. Levosimendan instead of phosphodiesterase inhibitors in this case is preferable. The maxim of hemodynamic management in cardiogenic shock is the transient use of inotropes and vasopressors in the lowest dose possible and only for as long as necessary. This means that one should continuously check whether the dose can be reduced. There are no mortality data demonstrating the utility of hemodynamic monitoring based on objective criteria—but it makes sense to use inotropes and vasopressors sparingly.
authors.affiliation: Medizinische Klinik II - Kardiologie, Angiologie, Internistische Intensivmedizin, St. Marienkrankenhaus Siegen, Kampenstr. 51, 57072, Siegen, Deutschland.
authors.forename: H
authors.initials: H
authors.lastname: Lemm
authors.forename: S
authors.initials: S
authors.lastname: Dietz
authors.forename: M
authors.initials: M
authors.lastname: Janusch
authors.forename: M
authors.initials: M
authors.lastname: Buerke
mesh_terms: D002309:Cardiology / Q000639:trends*; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D003422:Critical Care / Q000639:trends*; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D002316:Cardiotonic Agents